Bacteriophage-mediated microbiota modification to prevent colorectal cancer development
噬菌体介导的微生物群修饰可预防结直肠癌的发展
基本信息
- 批准号:10467179
- 负责人:
- 金额:$ 17.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-10 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAntibioticsApcMin/+ miceApplied ResearchBacteriaBacterial InfectionsBacteriophagesBuffersCancer Cell GrowthCessation of lifeClinicalColitisColitis associated colorectal cancerColonic NeoplasmsColorectal CancerDataDevelopmentDiseaseEquilibriumEscherichia coliEvaluationFecesFutureGerm-FreeHumanImmune responseImmune systemIn VitroIndividualInfectionInflammationInflammatory Bowel DiseasesInterventionIntestinesIslandKlebsiella pneumoniaeKnowledgeLaboratoriesMalignant NeoplasmsMediatingMissionModelingModificationMonitorMusNecrotizing EnterocolitisOutcomePathogenicityPhase I Clinical TrialsPre-Clinical ModelPrevention strategyPreventiveRandomizedResearchRibosomal DNARoleSafetySterilityTestingTherapeuticTimeTissuesTranslatingUnited States National Institutes of HealthVirusantimicrobialbacteriomebasecarcinogenesiscolorectal cancer preventioncommensal bacteriadrinking waterfightinggerm free conditiongut colonizationgut inflammationgut microbiotahost microbiotaimproved outcomeinnovationinsightmicrobial compositionmicrobiomemicrobiotamicroorganismmurine colitisneonatenormal microbiotapathobiontpathogenpolyketide synthasepreventrestorationtooltreatment responsetumortumor growthtumorigenesis
项目摘要
PROJECT SUMMARY
Colorectal cancer remains as the second most lethal cancer and the third most prevalent malignant tumor
worldwide. An intestinal colonization with Klebsiella pneumoniae carrying a pathogenic polyketide synthase
(pks) island was shown by Dr. Jobin laboratory to singly induce intestinal inflammation and influence colorectal
cancer in a pre-clinical model. Restoration of the normal balance of the gut flora and reduction or control of K.
pneumoniae concentration may curtail colorectal cancer cell growth and improve outcomes in the host.
Unfortunately, the current strategy to eliminate infectious microorganisms rely almost exclusively on antibiotic
strategy, which significantly disrupt microbiota balance and often cause adverse effects.
One innovative approach to bring precision in the intervention and restore the microbiome balance of the gut
flora is the use of bacteriophages (i.e., phages). Phages are natural entities capable of lysing specific
pathogens without disturbing the host’s normal flora while averting the collateral damage of antimicrobial
usage. Our preliminary data indicate that isolated phages can specifically eradicate pks-positive K.
pneumoniae in vitro without infecting commensal bacteria such as other K. pneumoniae and Escherichia coli
strains. Additionally, the presence of phages in the murine gut was maintained over time and did not trigger
any inflammation. Still, it is unclear how phages impact the bacterial microbiome, the host immune system, or
tumor growth. Hence, the central hypothesis for this project is that phages can balance the gut microbiota by
decreasing inflammation, controlling K. pneumoniae colonization, and preventing tumor growth in the host. The
objective of the current application is to define the interaction between phages, bacterial microbiome,
inflammation, and colonic tumor formation in a mouse model of colitis and a colitis-associated tumorigenesis.
The rationale for the proposed research is that the outcomes will provide supportive evidence for future
development and evaluation of a phage-based intervention in humans colonized with K. pneumoniae. We aim
to (1) evaluate the role of phages in selectively controlling K. pneumoniae colonization in mice and (2)
determine the therapeutic value of phages in K. pneumoniae-mediated colitis-associated tumorigenesis.
At the completion of this research, we expect to obtain new insights on the role of phages in controlling K.
pneumoniae colonization and preventing colonic tumor formation and inflammation without massive disruption
of microbiota network. Defining the interaction between phages, bacterial microbiome, inflammation, and
colonic tumor formation in a pre-clinical model can bring us a step closer to identifying phages as safe and
effective precise modulators of bacterial colonization and tumor growth in humans.
项目概要
结直肠癌仍然是第二大致命癌症和第三大流行恶性肿瘤
全世界。携带致病性聚酮合酶的肺炎克雷伯菌在肠道定植
Jobin博士实验室证明(pks)岛可单独诱发肠道炎症并影响结直肠
临床前模型中的癌症。恢复肠道菌群的正常平衡并减少或控制 K.
肺炎链球菌浓度可能会抑制结直肠癌细胞的生长并改善宿主的预后。
不幸的是,目前消除传染性微生物的策略几乎完全依赖抗生素
策略,这会显着破坏微生物群平衡并经常造成不利影响。
一种创新方法,可实现精确干预并恢复肠道微生物组平衡
菌群是噬菌体(即噬菌体)的使用。噬菌体是能够裂解特定噬菌体的自然实体
病原体,而不干扰宿主的正常菌群,同时避免抗菌药物的附带损害
用法。我们的初步数据表明,分离的噬菌体可以特异性根除 pks 阳性 K.
体外培养肺炎克雷伯菌,但不感染其他肺炎克雷伯菌和大肠杆菌等共生菌
菌株。此外,随着时间的推移,噬菌体在小鼠肠道中的存在得以维持,并且不会触发
任何炎症。尽管如此,目前还不清楚噬菌体如何影响细菌微生物组、宿主免疫系统或
肿瘤生长。因此,该项目的中心假设是噬菌体可以通过以下方式平衡肠道微生物群:
减少炎症,控制肺炎克雷伯菌定植,并防止宿主体内肿瘤生长。这
当前应用程序的目标是定义噬菌体、细菌微生物组、
结肠炎小鼠模型中的炎症和结肠肿瘤形成以及结肠炎相关的肿瘤发生。
拟议研究的基本原理是,结果将为未来提供支持性证据
对肺炎克雷伯菌定植的人类进行基于噬菌体的干预的开发和评估。我们的目标
(1) 评估噬菌体在选择性控制小鼠肺炎克雷伯菌定植中的作用,以及 (2)
确定噬菌体在肺炎克雷伯菌介导的结肠炎相关肿瘤发生中的治疗价值。
这项研究完成后,我们期望获得关于噬菌体在控制 K. 噬菌体中的作用的新见解。
肺炎链球菌定植并防止结肠肿瘤形成和炎症,而不会造成大规模破坏
微生物群网络。定义噬菌体、细菌微生物组、炎症和细菌之间的相互作用
临床前模型中结肠肿瘤的形成可以使我们更接近于识别噬菌体的安全性和有效性
人类细菌定植和肿瘤生长的有效精确调节剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lynn El Haddad其他文献
Lynn El Haddad的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lynn El Haddad', 18)}}的其他基金
Bacteriophage-mediated microbiota modification to prevent colorectal cancer development
噬菌体介导的微生物群修饰可预防结直肠癌的发展
- 批准号:
10620307 - 财政年份:2022
- 资助金额:
$ 17.82万 - 项目类别:
Bacteriophages as Modulators of Bacterial Colonization
噬菌体作为细菌定植的调节剂
- 批准号:
10540393 - 财政年份:2021
- 资助金额:
$ 17.82万 - 项目类别:
Bacteriophages as Modulators of Bacterial Colonization
噬菌体作为细菌定植的调节剂
- 批准号:
10350970 - 财政年份:2021
- 资助金额:
$ 17.82万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Studentship
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Research Grant
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Research Grant
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
ARC Future Fellowships
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 17.82万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 17.82万 - 项目类别:
Studentship














{{item.name}}会员




